Phathom Pharmaceuticals, Inc. (PHAT) Research

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

Market snapshot

Symbol
PHAT
Price
$10.88
Day change
-1.09%
Market cap
$867.7M
P/E ratio
-5.68x
52-week range
7.61-18.31
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$23.00

Peer companies

  • AnaptysBio, Inc. (ANAB)
  • BridgeBio Oncology Therapeutics Inc. (BBOT)
  • Bicara Therapeutics Inc. Common Stock (BCAX)
  • Kodiak Sciences Inc. (KOD)
  • Nurix Therapeutics, Inc. (NRIX)
  • Oculis Holding AG (OCS)
  • Sana Biotechnology, Inc. (SANA)
  • Septerna, Inc. (SEPN)

Recent insider activity

  • Parikh Asit — G-Gift (28000 shares) on 2026-05-22
  • Parikh Asit — G-Gift (28000 shares) on 2026-05-22
  • Parikh Asit — M-Exempt (17500 shares) on 2026-05-20
  • Parikh Asit — A-Award (24122 shares) on 2026-05-19
  • Parikh Asit — D-Return (17500 shares) on 2026-05-20

Open Phathom Pharmaceuticals, Inc. (PHAT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.